Despite growing demand, only about 36% of employers cover GLP-1 drugs for weight loss — a figure that has barely budged from last year.
Health & Wellness News
A New York Times opinion piece uses writer Caroline Calloway's personal essay about taking Ozempic — despite not being overweight — as a jumping-off point to examine how GLP-1 drugs are being used beyond their intended medical purpose.
According to a new Gallup poll, 11% of Americans are currently on a GLP-1 medication like Wegovy, with 15% having tried one at some point — a sharp rise from 6% just a year ago. The numbers highlight how quickly these drugs have gone from niche treatments to mainstream weight loss tools.
A new Gallup survey confirms that GLP-1 weight loss drug use has surged to record levels in the U.S., with 11% of Americans currently taking one of these medications. This represents a massive jump over the past two years and reflects growing mainstream acceptance of drugs like Ozempic and Wegovy.
A secret shopper study by Yale University researchers, published in JAMA, found that telehealth platforms are prescribing GLP-1 weight loss drugs with little medical oversight — confirming long-standing concerns from doctors.
A new Gallup poll shows GLP-1 drug use has surged dramatically, with 15% of U.S. adults having tried medications like Ozempic or Wegovy — up from just 6% in 2024. Currently, 11% of adults are actively taking one of these drugs. The trend coincides with declining obesity rates across the country.
Researchers are trying to quantify the long-term health benefits of GLP-1 drugs — like reduced risk of heart disease and diabetes — to determine if their steep cost is justified.
A nutritionist put together five recipes specifically aimed at helping people eat more protein and vegetables — two areas where most people fall short. The meals were tested firsthand by the writer, offering a real-world perspective on how practical and tasty they actually are.